SCHEMBL95742

SCHEMBL95742

[CH2]c1ccc(NS(=O)(=O)c2ccc(C(=O)O)cc2)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 2/20 0.71
CA9 Q16790 2/20 0.71
CA1 P00915 1/20 0.71
CA2 P00918 1/20 0.71
GAA P10253 1/20 0.61
GFER P55789 2/20 0.61
KMT2A Q03164 4/20 0.57
MEN1 O00255 3/20 0.57
MAPT P10636 2/20 0.57
POLB P06746 2/20 0.57
HPGD P15428 1/20 0.54
ITGA1 P56199 1/20 0.54
ALDH1A1 P00352 1/20 0.53
PKM P14618 1/20 0.53
WDR5 P61964 2/20 0.53
CYP2C9 P11712 1/20 0.52
ATIC P31939 1/20 0.52
CYP2C19 P33261 1/20 0.52
HSD17B10 Q99714 1/20 0.52
IDO1 P14902 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7932062 0.85 CA12 (0.73) CA12CA9CA1CA2GAA
SCHEMBL893905 0.84 CA12 (0.73) CA12CA9CA1CA2GAA
SCHEMBL3715141 0.84 CA12 (0.75) CA12CA9CA1CA2GAA
SCHEMBL1028840 0.83 CA1 (0.71) CA12CA9CA1CA2GAA
SCHEMBL1834055 0.83 CA12 (0.71) CA12CA9CA1CA2GAA
SCHEMBL9285136 0.83 WDR5 (0.74) CA12CA9CA1CA2GAA
SCHEMBL28036324 0.83 CA9 (0.77) CA12CA9CA1CA2GAA
SCHEMBL1030477 0.83 GFER (0.83) CA12CA9CA1CA2GAA
SCHEMBL15482013 0.82 HDAC8 (0.71) CA12CA9CA1CA2GAA
SCHEMBL12338860 0.82 GFER (0.86) CA12CA9CA1CA2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362252-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-01-29 US disclosed
EP-1797082-B1 CARBOSTYRIL COMPOUND OTSUKA PHARMA CO LTD (JP) 2012-08-29 EP disclosed
EP-2426128-A1 Carbostyril compound Otsuka Pharmaceutical Co., Limited (JP) 2012-03-07 EP disclosed
US-20100261705-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. 2010-10-14 US disclosed
US-7777038-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-08-17 US disclosed
US-20090326008-A1 NF-kappa B Inhibitor OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-12-31 US disclosed
EP-2043644-A1 NF- B INHIBITOR Otsuka Pharmaceutical Co., Ltd. (JP) 2009-04-08 EP disclosed
WO-2008010601-A1 NF- ϰB INHIBITOR OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2008-01-24 WO disclosed
US-20070179173-A1 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-02 US disclosed
EP-1797082-A1 CARBOSTYRIL COMPOUND Otsuka Pharmaceutical Company, Limited (JP) 2007-06-20 EP disclosed
WO-2006035954-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-04-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326008-A1 NF-kappa B Inhibitor NFKBIA, NFKB2, IKBKB CA12 3743/4885CA9 2466/4885CA1 3276/4885
US-20070179173-A1 Carbostyril compound GTF2F1, F3, GTF2F2 CA12 1180/4885CA9 895/4885CA1 2592/4885
US-20100261705-A1 CARBOSTYRIL COMPOUND GTF2F1, F3, GTF2F2 CA12 1180/4885CA9 895/4885CA1 2592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.